1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Ward, B.P. Ma, D. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C4 H9 N O2 103.120 n ALPHA-AMINOISOBUTYRIC ACID L-peptide linking C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H9 N O4 147.129 GAMMA-L-GLUTAMIC ACID L-GLUTAMIC ACID L-gamma-peptide, C-delta linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking H2 N 16.023 AMINO GROUP non-polymer C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C16 H32 O2 256.424 PALMITIC ACID non-polymer C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking To be Published 0353 Structural Changes Associated with Peptide Lipidation Broaden Biological Function 10.2210/pdb2m5p/pdb pdb_00002m5p 3446.849 Glucagon 1 syn polymer 147.129 GAMMA-L-GLUTAMIC ACID 2 syn non-polymer 256.424 PALMITIC ACID 1 syn non-polymer no yes H(AIB)QGTFTSDYSKKLD(AIB)RRAQDFVQWLMNT(NH2) HAQGTFTSDYSKKLDARRAQDFVQWLMNTX X polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_database_status struct_conn struct_ref_seq_dif repository Initial release Database references Derived calculations Other 1 0 2013-03-27 1 1 2023-06-14 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data _struct_conn.pdbx_dist_value _struct_conn.pdbx_leaving_atom_flag _struct_conn.ptnr1_auth_comp_id _struct_conn.ptnr1_auth_seq_id _struct_conn.ptnr1_label_asym_id _struct_conn.ptnr1_label_atom_id _struct_conn.ptnr1_label_comp_id _struct_conn.ptnr1_label_seq_id _struct_conn.ptnr2_auth_comp_id _struct_conn.ptnr2_auth_seq_id _struct_conn.ptnr2_label_asym_id _struct_conn.ptnr2_label_atom_id _struct_conn.ptnr2_label_comp_id _struct_conn.ptnr2_label_seq_id _struct_ref_seq_dif.details HELIX DETERMINATION METHOD: AUTHOR DETERMINED BMRB Y RCSB 2013-03-03 REL REL REL REL GGL GAMMA-L-GLUTAMIC ACID PLM PALMITIC ACID 9606 human Homo sapiens sample structures with the lowest energy 100 10 2D 1H-1H TOCSY 2D 1H-1H NOESY 0.7 mM 20 mM 0.02 4.7 ambient 298 K simulated annealing 1 closest to the average 0.7 mM peptide, 20 mM sodium phosphate, 90% H2O/10% D2O 90% H2O/10% D2O BRUNGER refinement XPLOR-NIH 800 Varian Varian Uniform NMR System LYX 13 2 GGL GGL 101 X LYX 13 2 GGL GGL 102 X LYX 13 3 PLM PLM 103 X HIS 1 n 1 HIS 1 X AIB 2 n 2 AIB 2 X GLN 3 n 3 GLN 3 X GLY 4 n 4 GLY 4 X THR 5 n 5 THR 5 X PHE 6 n 6 PHE 6 X THR 7 n 7 THR 7 X SER 8 n 8 SER 8 X ASP 9 n 9 ASP 9 X TYR 10 n 10 TYR 10 X SER 11 n 11 SER 11 X LYS 12 n 12 LYS 12 X LYX 13 n 13 LYS 13 X LEU 14 n 14 LEU 14 X ASP 15 n 15 ASP 15 X AIB 16 n 16 AIB 16 X ARG 17 n 17 ARG 17 X ARG 18 n 18 ARG 18 X ALA 19 n 19 ALA 19 X GLN 20 n 20 GLN 20 X ASP 21 n 21 ASP 21 X PHE 22 n 22 PHE 22 X VAL 23 n 23 VAL 23 X GLN 24 n 24 GLN 24 X TRP 25 n 25 TRP 25 X LEU 26 n 26 LEU 26 X MET 27 n 27 MET 27 X ASN 28 n 28 ASN 28 X THR 29 n 29 THR 29 X THR 29 n 30 NH2 30 X author_defined_assembly 1 monomeric X AIB 2 ALPHA-AMINOISOBUTYRIC ACID A AIB 2 ALA X AIB 16 ALPHA-AMINOISOBUTYRIC ACID A AIB 16 ALA 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 X X HZ1 HE LYS ARG 13 17 1.27 2 X X O H AIB GLY 2 4 1.32 4 X X HZ1 HH21 LYS ARG 13 17 1.27 6 X X H H GLN ASP 20 21 1.30 8 X X HE2 HE22 HIS GLN 1 3 1.19 8 X X HZ2 H LYS GGL 12 102 1.23 8 X X HH21 HH11 ARG ARG 17 18 1.26 1 X AIB 2 -151.50 56.83 1 X GLN 3 -19.77 -40.96 1 X THR 5 -47.44 -17.14 1 X PHE 6 -109.63 -65.28 1 X SER 8 -61.95 1.34 1 X LYS 13 170.86 -95.25 1 X AIB 16 -66.35 5.80 1 X ALA 19 74.68 -57.57 1 X GLN 20 162.91 -23.82 1 X LEU 26 -101.23 56.58 1 X MET 27 -156.74 -52.60 2 X AIB 2 173.92 -17.75 2 X GLN 3 52.34 -51.88 2 X THR 5 -47.38 -17.95 2 X THR 7 -62.71 5.93 2 X SER 8 -65.47 -91.38 2 X ASP 9 -25.87 -59.17 2 X LYS 12 -150.54 69.62 2 X LYS 13 63.97 -112.66 2 X ARG 18 -66.85 4.64 2 X ALA 19 80.12 -55.10 2 X GLN 20 158.41 -24.94 2 X ASP 21 -52.68 -9.73 2 X TRP 25 -39.39 -73.31 2 X LEU 26 -82.35 33.26 2 X MET 27 -139.33 -72.70 3 X AIB 2 -150.84 56.68 3 X GLN 3 -20.54 -40.44 3 X SER 8 -42.77 -81.00 3 X ASP 9 -25.65 -52.16 3 X LYS 12 -166.40 -76.55 3 X LYS 13 -168.13 -86.36 3 X AIB 16 -62.95 5.74 3 X ALA 19 76.53 -52.36 3 X GLN 20 138.84 63.83 3 X ASP 21 -154.22 -50.09 3 X PHE 22 23.67 -123.06 3 X MET 27 -122.52 -59.29 4 X AIB 2 -151.18 56.74 4 X GLN 3 -20.33 -40.67 4 X SER 8 -50.79 -7.17 4 X SER 11 -133.80 -34.26 4 X LYS 13 160.49 -90.14 4 X ALA 19 73.04 -52.56 4 X GLN 20 157.70 -25.79 4 X LEU 26 -94.24 43.13 4 X MET 27 -137.07 -47.77 5 X AIB 2 -150.82 57.27 5 X GLN 3 -19.06 -41.17 5 X THR 5 -47.82 -15.83 5 X THR 7 -62.06 5.64 5 X SER 8 -69.22 -104.66 5 X ASP 9 -10.72 -52.56 5 X LYS 12 -91.26 -91.09 5 X LYS 13 -153.10 -81.27 5 X AIB 16 -77.55 40.29 5 X ALA 19 74.30 -49.33 5 X GLN 20 132.11 54.83 5 X ASP 21 -136.77 -40.22 5 X PHE 22 33.57 -88.11 5 X VAL 23 -107.11 43.43 5 X GLN 24 38.65 29.49 6 X AIB 2 -151.61 56.97 6 X GLN 3 -20.25 -40.50 6 X THR 5 -46.98 -15.20 6 X PHE 6 -107.96 -62.33 6 X SER 8 -64.65 1.34 6 X ASP 9 -105.89 -63.10 6 X LYS 13 31.44 -99.04 6 X AIB 16 -62.89 8.43 6 X ARG 18 -146.15 -109.69 6 X ALA 19 46.90 12.24 6 X GLN 20 -165.53 0.58 6 X TRP 25 -37.95 -74.70 6 X LEU 26 -77.32 31.94 7 X AIB 2 -151.42 56.38 7 X GLN 3 -20.36 -40.30 7 X THR 5 -44.32 -18.47 7 X SER 8 -56.59 -6.32 7 X ASP 9 -92.18 -64.15 7 X LYS 12 -109.97 -74.65 7 X LYS 13 -149.23 -78.15 7 X ASP 15 -75.11 -76.61 7 X AIB 16 0.34 -64.95 7 X ARG 17 -34.81 -39.54 7 X ARG 18 -129.23 -122.44 7 X ALA 19 44.22 17.68 7 X GLN 20 -172.54 34.32 7 X ASP 21 -170.34 -40.77 7 X PHE 22 34.01 -89.14 7 X VAL 23 -103.83 42.07 7 X GLN 24 41.85 24.80 7 X ASN 28 -47.48 -15.64 8 X AIB 2 -148.51 58.21 8 X GLN 3 -15.35 -43.75 8 X LYS 12 -145.98 -89.04 8 X LYS 13 -162.99 -85.16 8 X ARG 18 -132.94 -132.35 8 X ALA 19 56.33 10.00 8 X GLN 20 -165.10 18.00 8 X ASP 21 -158.21 -44.09 8 X PHE 22 33.99 -88.30 8 X VAL 23 -98.34 42.34 8 X LEU 26 41.82 26.36 8 X MET 27 80.83 94.74 8 X ASN 28 39.78 33.79 9 X AIB 2 -150.77 56.26 9 X GLN 3 -17.33 -41.51 9 X THR 5 -45.49 -17.19 9 X PHE 6 -119.23 -70.37 9 X THR 7 -62.76 7.43 9 X SER 8 -72.45 -90.95 9 X ASP 9 -20.02 -43.93 9 X LYS 12 -128.94 -81.25 9 X LYS 13 -174.05 -84.25 9 X ARG 18 -126.70 -125.13 9 X ALA 19 48.84 14.56 9 X GLN 20 -170.41 20.24 9 X ASP 21 -162.87 -58.49 9 X PHE 22 35.76 -88.67 9 X VAL 23 -95.94 44.60 9 X LEU 26 41.42 25.16 9 X MET 27 81.19 94.30 9 X ASN 28 39.44 27.10 10 X AIB 2 -150.67 57.07 10 X GLN 3 -19.67 -40.92 10 X THR 5 -44.72 -17.56 10 X ASP 9 -95.87 -63.35 10 X LYS 12 -113.95 -80.87 10 X LYS 13 -147.90 -102.43 10 X ASP 15 -112.91 53.02 10 X AIB 16 -164.41 -12.46 10 X ARG 18 -77.80 30.04 10 X ALA 19 73.61 -55.07 10 X GLN 20 161.38 -25.69 10 X ASP 21 -49.03 -15.47 10 X ASN 28 77.87 -18.49 Solution structure of lipidated glucagon analog in water 1 N N 2 N N 2 N N 3 N N X THR 7 A THR 7 HELX_P X LYS 12 A LYS 12 5 1 6 X ASP 21 A ASP 21 HELX_P X TRP 25 A TRP 25 1 2 5 covale 1.320 both X HIS 1 A C HIS 1 1_555 X AIB 2 A N AIB 2 1_555 covale 1.320 both X AIB 2 A C AIB 2 1_555 X GLN 3 A N GLN 3 1_555 covale 1.325 one X LYS 13 A NZ LYS 13 1_555 X GGL 101 B CD GGL 1_555 covale 1.329 both X ASP 15 A C ASP 15 1_555 X AIB 16 A N AIB 16 1_555 covale 1.331 both X AIB 16 A C AIB 16 1_555 X ARG 17 A N ARG 17 1_555 covale 1.220 both X THR 29 A C THR 29 1_555 X NH2 30 A N NH2 30 1_555 covale 1.318 both X GGL 101 B N GGL 1_555 X GGL 102 C CD GGL 1_555 covale 1.336 both X GGL 102 C N GGL 1_555 X PLM 103 D C1 PLM 1_555 LIPID BINDING PROTEIN GLUCAGON, DIABETES, OBESITY, LIPIDATED, LIPID BINDING PROTEIN GLUC_HUMAN UNP 1 53 P01275 HSQGTFTSDYSKYLDSRRAQDFVQWLMNT 53 81 2M5P 1 29 P01275 X 1 1 29 1 SER engineered mutation AIB 2 2M5P X P01275 UNP 54 2 1 TYR engineered mutation LYS 13 2M5P X P01275 UNP 65 13 1 SER engineered mutation AIB 16 2M5P X P01275 UNP 68 16 1 amidation NH2 30 2M5P X P01275 UNP 30 BINDING SITE FOR LINKED RESIDUES X 101 to 103 Software 8 X GLN 3 A GLN 3 8 1_555 X THR 5 A THR 5 8 1_555 X SER 8 A SER 8 8 1_555 X LYS 12 A LYS 12 8 1_555 X LYS 13 A LYS 13 8 1_555 X ARG 17 A ARG 17 8 1_555 X ARG 18 A ARG 18 8 1_555 X LEU 26 A LEU 26 8 1_555 1 P 1